World Journal of Pediatrics

, Volume 5, Issue 4, pp 316–318 | Cite as

Theophylline-associated status epilepticus in an infant: pharmacokinetics and the risk of suppository use

  • Zenichiro Kato
  • Atsushi Yamagishi
  • Mitsuhiro Nakamura
  • Naomi Kondo



Theophylline has been widely used to treat asthma, but recent studies have revealed that the possible risks for seizure may result in the revision of the therapeutic guidelines.


An 8-month-old boy who had been treated with oral sustained-release theophylline and additional aminophylline suppository was hospitalized. A combination of diazepam, lidocaine and thiopental was required to stop his convulsion.


The pharmacokinetic study indicated that the usage of a sustained-release formula should not usually be over 15 mg/ml, but the additional use of an aminophylline suppository elevated the concentration to over 20 mg/ml and resulted in the severe adverse effects.


The parents of children and also physicians should be educated to ensure the proper use of the suppository formula.

Key words

convulsion pharmacokinetics suppository theophylline 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Dunn DW, Parekh HU. Theophylline and status epileptics in children. Neuropediatrics 1991;22:24–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Nolke AC. Severe toxic effects from aminophylline and theophylline suppositories in children. JAMA 1956;161:693–697.Google Scholar
  3. 3.
    Ooniwa T, Kuwahata K, Matsumoto T, Watanabe K, Yamashita K, Shinya H, et al. The Clinical Report 1985;19:444–454.Google Scholar
  4. 4.
    Kato Z, Fukutomi O, Yamazaki M, Kondo N, Imaeda N, Orii T. Prediction of steady-state serum theophylline concentration in children by fi rst-order and zero-order absorption models. Int J Clin Pharmacol Ther 1994;32:231–234.PubMedGoogle Scholar
  5. 5.
    Kato Z, Yasuda K, Shimozawa N, Kondo N, Horiuchi T. Theophylline-associated status epilepticus resulting in quadriplegia. Ann Allergy Asthma Immunol 1997;78:332.PubMedGoogle Scholar
  6. 6.
    Kato Z, Fukutomi O, Kondo N. Developmental changes of unbound theophylline. Ann Allergy Asthma Immunol 1998;80:517.PubMedCrossRefGoogle Scholar
  7. 7.
    Kato Z, Fukutomi O, Kondo N. Intrinsic factors for unbound theophylline. J Investig Allergol Clin Immunol 2002;12:217–219.PubMedGoogle Scholar
  8. 8.
    Yoshikawa H. First-line therapy for theophylline-associated seizures. Acta Neurol Scand Suppl 2007;186:57–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Haruyama W, Fuchigami T, Noguchi Y, Endo A, Hashimoto K, Inamo Y, et al. The relationship between drug treatment and the clinical characteristics of febrile seizures. World J Pediatr 2008;4:202–205.CrossRefPubMedGoogle Scholar
  10. 10.
    Medical Economics Staff. Drug information for the health care professional: USP DI, 15th ed, Macromedix, 1995.Google Scholar

Copyright information

© Children's Hospital, Zhejiang University School of Medicine and Springer Berlin Heidelberg 2009

Authors and Affiliations

  • Zenichiro Kato
    • 1
  • Atsushi Yamagishi
    • 1
  • Mitsuhiro Nakamura
    • 2
  • Naomi Kondo
    • 1
  1. 1.Department of Pediatrics, Graduate School of MedicineGifu UniversityGifuJapan
  2. 2.Department of PharmacyGifu University HospitalGifuJapan

Personalised recommendations